文献速递湿疹皮炎与荨麻疹

一项全国性104周真实世界研究:度普利尤单抗治疗成人特应性皮炎在头颈部皮炎中无效

A nationwide 104 weeks real-world study of dupilumab in adults with atopic dermatitis: Ineffectiveness in head-and-neck dermatitis.
PubMed 文献 · J Eur Acad Dermatol Venereol · 2023-01-21

丹麦全国性队列纳入347例接受度普利尤单抗治疗的中重度特应性皮炎成人患者,观察至104周。EASI中位数从基线18.0降至第104周1.7,第52周和第104周药物存活率分别为90%和86%。但头颈部AD在基线为76%、第104周仍达68%,结膜炎发生率为25%。

要点

  • 度普利尤单抗治疗104周药物存活率为86%,EASI中位数从基线18.0降至第104周1.7。
  • 头颈部AD基线占比76%,第104周仍达68%,度普利尤单抗未能有效治疗头颈部AD。
  • 35%患者报告不良事件,结膜炎最常见(25%),首次登记结膜炎的中位时间为201天。

核心结论

  • 2年药物存活率为86%,但度普利尤单抗未能有效治疗头颈部AD,25%患者发生结膜炎。

研究设计与样本

  • 丹麦全国性队列研究,纳入2017-2022年SCRATCH注册库中347例接受度普利尤单抗治疗的中重度AD成人患者,暴露观察至104周。

主要发现

  • EASI中位数从基线18.0(IQR 10.6-25.2)降至第4周6.5(IQR 3.5-11.6)、第16周3.7(IQR 1.2-6.2)、第52周2.0(IQR 0.8-3.6)、第104周1.7(IQR 0.8-3.8)。
  • 药物存活率第52周为90%,第104周为86%。
  • 头颈部AD比例基线为76%,第104周为68%。
  • 35%患者报告任何不良事件,结膜炎最常见(占全部患者的25%),首次登记结膜炎的中位时间为201天。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Evaluation of effectiveness and safety of new systemic treatments for atopic dermatitis (AD) after approval is important. There are few published data exceeding 52-week therapy with dupilumab. OBJECTIVES: To examine the safety, effectiveness and drug survival of dupilumab in a Danish nationwide cohort with moderate-to-severe AD up to 104 weeks exposure. METHODS: We included 347 adult patients with AD who were treated with dupilumab and registered in the SCRATCH registry during 2017-2022. RESULTS: At all visits, we observed improvement in AD severity measured by Eczema Area and Severity Index (EASI) [median (IQR)]. EASI score at baseline was 18.0 (10.6-25.2), at week 4: 6.5 (3.5-11.6), at week 16: 3.7 (1.2-6.2), at week 52: 2.0 (0.8-3.6), at week 104: 1.7 (0.8-3.8). While drug survival was high (week 52: 90%; week 104: 86%), AD in the head-and-neck area remained present in most patients at high levels; proportion with head-and-neck AD at baseline was 76% and 68% at week 104. 35% of patients reported any AE. Conjunctivitis was the most frequent (25% of all patients) and median time to first registration of conjunctivitis was 201 days. CONCLUSIONS: While 2-year drug survival was 86%, dupilumab was unable to effectively treat AD in the head-and-neck area, and conjunctivitis was found in 25% of patients.

来源:J Eur Acad Dermatol Venereol,查看原文。版权归原作者所有。

引用

  1. Vittrup I, Krogh NS, Larsen HHP, et al. A nationwide 104 weeks real-world study of dupilumab in adults with atopic dermatitis: Ineffectiveness in head-and-neck dermatitis. J Eur Acad Dermatol Venereol. 2023. PMID: 36606551. doi:10.1111/jdv.18849

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。